Form 4: Contineum Therapeutics Director Granted 14,750 Stock Options Under Compensation Plan

Contineum Therapeutics, Inc. Director Miralles Gines Diego was granted 14,750 stock options as part of the company's non-employee director compensation program.

Summary

• Miralles Gines Diego, a Director of Contineum Therapeutics, Inc. (CTNM), was granted 14,750 stock options.
• The options were granted on June 26, 2025, under the Issuer's 2024 Equity Incentive Plan.
• This grant is part of the Issuer's Non-Employee Director Compensation Program, which provides for automatic grants to non-employee directors following each regular annual meeting of stockholders.
• Each option has an exercise price of $4.01 per share.
• The options will vest in full on the earlier of June 26, 2026 (the one-year anniversary of the grant date) or the next regular annual meeting of stockholders, subject to continuous service.
• The expiration date for these stock options is June 25, 2035.
• Following this transaction, Miralles Gines Diego beneficially owns 14,750 derivative securities directly.

Sentiment

Score: 6

Explanation: The filing is neutral to slightly positive, as it represents a routine compensation event that aligns director interests with shareholders, without indicating any new operational or financial developments.

Positives

• The grant of stock options aligns the interests of the director with those of the shareholders, as the value of the options increases with the company's stock price.
• It demonstrates a structured and pre-defined compensation program for non-employee directors, indicating good corporate governance practices.

Future Outlook

The granted stock options are subject to a vesting schedule, which will occur in full on the earlier of June 26, 2026, or the next regular annual meeting of stockholders, contingent on the director's continuous service.

Management Comments

• Options granted under the Issuer's 2024 Equity Incentive Plan, pursuant to the Issuer's Non-Employee Director Compensation Program, as amended.
• The program states that upon the conclusion of each regular annual meeting of the Company's stockholders, each non-employee director who continues to serve as a member of the Company's Board of Directors thereafter will automatically be granted a stock option for 14,750 shares of the Company's Class A Common Stock.

Industry Context

The granting of stock options to non-employee directors is a common practice across various industries, particularly in biotechnology and pharmaceuticals, to attract and retain experienced board members and align their interests with long-term shareholder value.

Comparison to Industry Standards

• The practice of granting stock options as part of non-employee director compensation is a standard industry practice, comparable to compensation structures seen in companies like Amgen Inc. or Gilead Sciences, Inc., which also utilize equity-based incentives to align director and shareholder interests.
• The specific number of options (14,750) and the exercise price ($4.01) are specific to Contineum Therapeutics' compensation plan and current valuation, and would require a detailed peer group analysis to assess against specific industry benchmarks for similar-sized biotech companies.

Corporate Governance

Stakeholder Impact

• Shareholders: The grant of options aligns the director's financial incentives with the company's stock performance, potentially benefiting shareholders if the stock price increases.
• Employees: No direct impact mentioned, but the 2024 Equity Incentive Plan may also cover employee grants.

Next Steps

• The stock options will vest in full on the earlier of June 26, 2026, or the next regular annual meeting of stockholders, subject to continuous service.

Key Dates

Keywords

Contineum Therapeutics, CTNM, Stock Option, Director Compensation, SEC Form 4, Equity Incentive Plan, Insider Transaction, Corporate Governance